ストックスクリーナーアプリを入手
1.47
2.10%
0.04
前日終値:
$1.43
開ける：
$1.44
24時間の取引高:
186.41K
Relative Volume:
0.40
時価総額：
$79.43M
収益：
-
当期純損益:
$-151.16M
株価収益率:
-0.4949
EPS:
-2.97
ネットキャッシュフロー:
$-130.08M
1週間 パフォーマンス:
-5.19%
1か月 パフォーマンス:
-6.41%
6か月 パフォーマンス:
+194.77%
1年 パフォーマンス:
-18.44%
1日の値動き範囲:
$1.39
$1.51
1週間の範囲:
$1.37
$1.55
52週間の値動き範囲:
$0.404
$2.27
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
名前
Alx Oncology Holdings Inc
セクター
電話
650-466-7125
住所
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
ALXO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.465 | 77.53M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.08 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.46 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.69 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.74 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.31 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-13 | 開始されました | Jefferies | Buy |
| 2025-03-06 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2024-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | アップグレード | Jefferies | Hold → Buy |
| 2021-12-22 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-06 | 開始されました | UBS | Buy |
| 2021-02-10 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 開始されました | Credit Suisse | Outperform |
| 2020-08-11 | 開始されました | Jefferies | Buy |
| 2020-08-11 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Alx Oncology Holdings Inc (ALXO) 最新ニュース
Alx Oncology: A Study in Contrasting Market Sentiment - AD HOC NEWS
ALX Oncology (NASDAQ:ALXO) Lowered to “Sell” Rating by Wall Street Zen - Defense World
ALX Oncology (NASDAQ:ALXO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Alx Oncology rallies on strong phase 2 data for lymphoma therapy - MSN
Alx Oncology stock soars after impressive lymphoma treatment results By Investing.com - Investing.com UK
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ALX Oncology (Nasdaq:ALXO) Reports High Response Rates for Evorpacept Combo in Indolent B-cell NHL at ASH 2025 - Kalkine Media
ALXO: Promising Phase 2 Trial Results for Evorpacept in iNHL Tre - GuruFocus
Alx Oncology Holdings Inc. Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-Of-Care Treatment in Patients with Indolent B-Cell Non-Hodgkin Lymphoma, At Ashodgkinlymph - marketscreener.com
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting - Sahm
ALX Oncology (NASDAQ:ALXO) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
ALX Oncology (NASDAQ:ALXO) Stock Price Up 3.8%Here's Why - MarketBeat
Reviewing Harmony Biosciences (NASDAQ:HRMY) and ALX Oncology (NASDAQ:ALXO) - Defense World
Why ALX Oncology Holdings Inc. stock could benefit from AI revolutionMarket Growth Summary & High Accuracy Trade Signal Alerts - Newser
HER2-positive Gastric Cancer Clinical Trial Pipeline: Insights into a Growing Landscape with 20+ Companies Advancing Novel Treatments| DelveInsight - GlobeNewswire
How resilient is ALX Oncology Holdings Inc. stock in market downturnsMarket Trend Summary & Consistent Profit Trade Alerts - newser.com
Jefferies reiterates Buy rating on ALX Oncology stock, sees potential in cancer programs - Investing.com Canada
Can ALX Oncology Holdings Inc. hit a new high this month2025 Volatility Report & Daily Profit Maximizing Tips - newser.com
What analyst consensus says on ALX Oncology Holdings Inc. stockQuarterly Profit Summary & Consistent Growth Stock Picks - newser.com
Will ALX Oncology Holdings Inc. stock outperform Dow Jones index2025 Fundamental Recap & Accurate Entry/Exit Alerts - newser.com
Is ALX Oncology Holdings Inc. stock attractive for long term wealth buildingVolume Spike & Expert Curated Trade Setups - newser.com
Is ALX Oncology Holdings Inc. stock attractive for hedge fundsEntry Point & Consistent Growth Equity Picks - newser.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - Markets Financial Content
ALXO: Two high-value oncology programs advance toward key 2025 data with strong financial support - TradingView
Published on: 2025-11-19 06:30:37 - newser.com
Published on: 2025-11-19 06:25:55 - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Will ALX Oncology Holdings Inc. stock deliver long term returnsCEO Change & Entry Point Confirmation Signals - newser.com
Published on: 2025-11-18 23:37:11 - newser.com
Analyzing ALX Oncology Holdings Inc. with risk reward ratio charts2025 Trading Recap & Daily Growth Stock Tips - newser.com
Published on: 2025-11-18 12:31:34 - newser.com
ALX Oncology to Present at Upcoming Investor Conferences - The Manila Times
Published on: 2025-11-18 00:39:17 - newser.com
Alx Oncology Holdings Inc (ALXO) 財務データ
収益
当期純利益
現金流量
EPS
Alx Oncology Holdings Inc (ALXO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jun 30 '25 |
Sale |
0.43 |
1,532 |
659 |
88,820 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 19 '25 |
Sale |
1.15 |
550 |
633 |
87,352 |
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
| Pinto Shelly | Interim CFO |
Jan 06 '25 |
Sale |
1.80 |
2,221 |
3,998 |
87,902 |
0.39%
0.31%
大文字化:
|
ボリューム (24 時間):